Switzerland · Delayed Price · Currency is CHF Sonova Holding AG Earnings Call Transcripts
Fiscal Year 2026
-
Delivered strong sales and profit growth, driven by innovation and market share gains in hearing instruments and retail, while cochlear implants faced headwinds. Outlook for 2026-2027 is positive, with continued above-market growth and margin expansion expected.
-
A refreshed strategy aims for CHF 6 billion revenue by FY 2031, focusing on hearing care, innovation, and operational excellence. Growth will be driven by market share gains, Asia expansion, and disciplined M&A, with midterm targets of 5%-10% sales CAGR and 7%-12% core EBIT CAGR.
-
Sales and EBITDA grew strongly in local currencies, led by innovation in hearing instruments and audiological care, while FX and market headwinds impacted reported results. Guidance for 5-9% sales growth and 14-18% EBITDA growth at constant FX is reiterated.
Fiscal Year 2025
-
Solid full-year growth and market share gains were achieved across all segments, with strong product launches and structural cost improvements driving profitability. Guidance for FY 2025 anticipates 5%-9% top-line growth and 11%-15% normalized EBITDA growth, factoring in market headwinds and tariff risks.
-
Sales grew 5.9% in local currencies, led by hearing instruments and cochlear implants, despite market headwinds and higher launch costs. Strong H2 momentum is expected from new products and cost actions, with margin expansion anticipated as launch costs subside.
Fiscal Year 2024
-
Maintaining its growth targets, the company launched the Infinio and Sphere Infinio platforms, featuring breakthrough AI-driven speech clarity and robust connectivity. Strong initial demand, especially for Sphere Infinio, is driving a shift in product mix, while operational improvements and brand harmonization support global expansion.